NASDAQ: CPRXCatalyst Pharmaceuticals Inc Stock
$22.52+0.33 (+1.49%)
Updated Apr 17, 2025
CPRX Price
$22.52
Fair Value Price
N/A
Market Cap
$2.74B
52 Week Low
$14.47
52 Week High
$26.16
P/E
16.32x
P/B
3.76x
P/S
5.03x
PEG
0.75x
Dividend Yield
N/A
Revenue
$491.73M
Earnings
$163.89M
Gross Margin
86%
Operating Margin
43.98%
Profit Margin
33.3%
Debt to Equity
0.17
Operating Cash Flow
$240M
Beta
1.06
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CPRX Overview
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CPRX's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CPRX
Ranked#4 of 463
Ranked#4 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important CPRX news, forecast changes, insider trades & much more!
CPRX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CPRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CPRX ($22.52) is trading above its intrinsic value of $17.83, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CPRX is good value based on its earnings relative to its share price (16.32x), compared to the US market average (27.98x)
P/E vs Market Valuation
CPRX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more CPRX due diligence checks available for Premium users.
Valuation
CPRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
16.32x
Industry
-177.72x
Market
27.98x
CPRX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CPRX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CPRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.76x
Industry
4.05x
CPRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CPRX price to earnings growth (PEG)
For valuing profitable companies with growth potential
CPRX is good value based... subscribe to Premium to read more.
PEG Value Valuation
CPRX's financial health
Profit margin
Revenue
$141.8M
Net Income
$55.9M
Profit Margin
39.4%
CPRX's Earnings (EBIT) of $216.26M... subscribe to Premium to read more.
Interest Coverage Financials
CPRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$851.4M
Liabilities
$123.8M
Debt to equity
0.17
CPRX's short-term assets ($623.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CPRX's short-term assets ($623.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CPRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CPRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$70.9M
Investing
-$88.0k
Financing
$4.4M
CPRX's operating cash flow ($239.81M)... subscribe to Premium to read more.
Debt Coverage Financials
CPRX vs Biotech Stocks
Catalyst Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.